{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete response (CR)"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Partial response (PR)"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Stable disease (SD) >= 6 months"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Stable disease (SD) < 6 months"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Progressive disease (PD)"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Not evaluable (NE)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Defined as the percentage of subjects having complete response (CR) or partial response (PR). The best overall response was defined as the best response recorded before and including the first event of Progressive disease (PD).","groups":[{"description":"Part 2 / treatment group A (TGA): dose titration was to determine the feasibility of intraparticipant dose titration using Protocol-defined criteria. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG000","title":"Part 2 / Treatment Group A: 20 MG BID INCB054329"},{"description":"Part 2 / treatment group C (TGC): dose titration was to determine the feasibility of intraparticipant dose titration using Protocol-defined criteria. Treatment Group C included multiple myeloma.","id":"OG001","title":"Part 2 / Treatment Group C: 20 mg BID INCB054329"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"As a result of early termination of the study, only participants in Part 2 of the study were evaluated; Treatment Group C was not evaluated due to early termination from the study.","reportingStatus":"POSTED","timeFrame":"Baseline through end of study, up to 6 months","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}